Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: GSK/Apeiron, Cephalon/Mepha, Medco/DNA Direct...

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal

Abbott broadens its approach to new cancer therapies by linking up with the Danish company EpiTherapeutics on modifying epigenetic regulation.

Business News In Brief

Roche primary care "scale up": Ahead of a potential launch of the GLP-1 analog taspoglutide for the treatment of type 2 diabetes, Roche will need to "scale up" its primary care infrastructure, Pharmaceuticals Chief Operating Officer Pascal Soriot said during an investor meeting in New York Feb. 4. If approved, the drug would compete against entrenched rivals, including Lilly/Amylin's established Byetta (exenatide) and Novo Nordisk's recently approved Victoza (liraglutide). Still, Soriot maintained, "the scale-up is not as big as people ultimately think." In the U.S., the company already has a primary care infrastructure in place, he said, including 570 reps visiting physician offices and 250 visiting clinics. The filing for taspoglutide has been pushed back to 2011 from an earlier target of 2010 due to a delay in the start of a large cardiovascular safety study, T-EMERGE 8. Roche is expecting to file once interim results are in hand

Business News In Brief

Roche primary care "scale up": Ahead of a potential launch of the GLP-1 analog taspoglutide for the treatment of type 2 diabetes, Roche will need to "scale up" its primary care infrastructure, Pharmaceuticals Chief Operating Officer Pascal Soriot said during an investor meeting in New York Feb. 4. If approved, the drug would compete against entrenched rivals, including Lilly/Amylin's established Byetta (exenatide) and Novo Nordisk's recently approved Victoza (liraglutide). Still, Soriot maintained, "the scale-up is not as big as people ultimately think." In the U.S., the company already has a primary care infrastructure in place, he said, including 570 reps visiting physician offices and 250 visiting clinics. The filing for taspoglutide has been pushed back to 2011 from an earlier target of 2010 due to a delay in the start of a large cardiovascular safety study, T-EMERGE 8. Roche is expecting to file once interim results are in hand

Related Content

Topics

UsernamePublicRestriction

Register

PS051903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel